Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company.
Our lead product, Feraccru®, is a novel oral treatment for iron deficiency anaemia (IDA). Following receipt of marketing authorisation in early 2016, Feraccru is now commercially available for use initially in patients with inflammatory bowel disease associated IDA.
The UK was the launch market and Feraccru will become available in Germany and more broadly across Europe later in 2016 and into 2017.Read more
Our second asset, PT20, is a treatment for hyperphosphatemia that has successfully completed a first pivotal trial. In addition, the Group has earlier stage assets that it intends to develop or out-license over time.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. Our most advanced pipeline asset, PT20, has completed its first pivotal study with one further pivotal Phase 3 study planned in order to seek regulatory approval in major markets.Read more